Close Menu

myeloproliferative disease

The method allows for the annotation of cells by their genotype and capture of single-cell transcriptomes, even when the cells aren't morphologically distinct.

Members of the Beat AML consortium uncovered relationships between somatic mutations, gene expression profiles, and sensitivity to more than 100 drugs.

In combination with other clinical data, the genomic subtypes were able to predict patients' outcomes and could be used to help guide treatments.

The working group reviewed data to identify a minimum of 34 commonly mutated genes that should be included in pan-myeloid targeted panels.

The US Food and Drug Administration cleared Qiagen's Ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all myeloproliferative neoplasms

The test runs on Qiagen's Rotor-Gene Q MDx system and is designed to qualitatively detect the JAK2 V617F/G1849T allele in genomic DNA from whole blood.

The study expands on the known genetic subtypes, shows that they are correlated with clinical outcome, and paves the way for better subtype-driven patient management. 

A multistage GWAS suggests inherited SNPs at four sites in the genome can contribute to the risk of developing myeloproliferative neoplasms.

Researchers have found that the order in which TET2 and JAK2 mutations are acquired may impact drug response and disease progression.

The 95-gene test is for detecting leukemia, myelodysplastic syndromes, and myeloproliferative disorders and can return results in less than one week.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.